Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Patients with metastatic breast cancer who:
Patients are excluded if they:
The study is being conducted by researchers at Cedars-Sinai Medical Center. Contact Bethany Wendel, RN, Research Coordinator by phone at 310-967-4339 or by email.
This trial will evaluate the use of the immunotherapy agent, Pembrolizumab, (Keytruda) in people with advanced breast cancer associated with a BRCA mutation. The main objective is to examine overall response rate of pembrolizumab single agent therapy in advanced BRCA-mutated breast cancer.
Visit clinicaltrials.gov for more information.
This is an open-label, single-arm study.
Principal Investigator: Monica Mita, MD, Cedars-Sinai Medical Center